"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 5 | 2 | 7 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 4 | 5 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Venugopal SV, Caggia S, Gambrell-Sanders D, Khan SA. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. Prostate. 2020 04; 80(5):412-423.
-
Basar MA, Williamson K, Roy SD, Finger DS, Ables ET, Duttaroy A. Spargel/dPGC-1 is essential for oogenesis and nutrient-mediated ovarian growth in Drosophila. Dev Biol. 2019 10 15; 454(2):97-107.
-
Hu LT, Zhu BL, Lai YJ, Long Y, Zha JS, Hu XT, Zhang JH, Chen GJ. HMGCS2 promotes autophagic degradation of the amyloid-ß precursor protein through ketone body-mediated mechanisms. Biochem Biophys Res Commun. 2017 04 29; 486(2):492-498.
-
Alshaman R, Truong L, Oyekan A. Role of mechanistic target of rapamycin (mTOR) in renal function and ischaemia-reperfusion induced kidney injury. Clin Exp Pharmacol Physiol. 2016 Nov; 43(11):1087-1096.
-
Lee R, Foin N, Ng J, Allen J, Soh N, Ang I, Shim W, Torii R, Wong P. Early coverage of drug-eluting stents analysed by optical coherence tomography: evidence of the impact of stent apposition and strut characteristics on the neointimal healing process. EuroIntervention. 2016 Aug 05; 12(5):e605-14.
-
Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA. The Enigma of Rapamycin Dosage. . 2016 Mar; 15(3):347-53.
-
Saqcena M, Patel D, Menon D, Mukhopadhyay S, Foster DA. Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. . 2015; 14(14):2285-92.
-
Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA. Rapamycin-induced G1 cell cycle arrest employs both TGF-ß and Rb pathways. Cancer Lett. 2015 May 01; 360(2):134-40.
-
Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, Foster DA. 5-Aminoimidazole-4-carboxamide-1-ß-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. . 2015; 14(20):3331-9.
-
Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.